# Indocyanine green (Renew Pharmaceuticals)

Source: https://onco.cc/drugs/renew-indocyanine-green/  
OnCo record `renew-indocyanine-green` (Imaging agent). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

This is indocyanine green, a glowing dye, as developed by Renew Pharmaceuticals for liver cancer. The FDA has given it orphan drug status as a diagnostic for managing hepatocellular carcinoma, the commonest liver cancer.

## Summary

Renew Pharmaceuticals supplies indocyanine green imaging agents under the Diagnostic Green brand. On 30 September 2026 the FDA granted orphan drug designation to indocyanine green as a diagnostic for the management of hepatocellular carcinoma (HCC), sponsored by Renew Pharmaceuticals Limited. A designation is not an approval, and the record does not describe the planned use or trials; this record carries the designation only.

## Fields

- Kind: Imaging agent
- Last checked: 2026-11-04
- Also known as: ICG; Diagnostic Green indocyanine green
- Tags: pipeline; orphan-designation
- Modality: Near-infrared fluorescence imaging agent
- Mechanism: Indocyanine green is a dye that fluoresces under near-infrared light; given into a vein it is taken up and cleared by the liver, which is the property used to show liver tissue and tumours during surgery.

## Sources

- FDA orphan designation record: https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1100325
- Renew Pharmaceuticals: https://renewpharmaceuticals.com/

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- technologies: [Fluorescence-guided surgery](https://onco.cc/technologies/fluorescence-guided-surgery/)
- companies: [Renew Pharmaceuticals](https://onco.cc/companies/renew-pharmaceuticals/)

---
JSON: https://onco.cc/api/v1/entities/renew-indocyanine-green.json